The DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Tissue-specific tumorigenesis: context matters
Open accessAbstract
How can we treat cancer more effectively? Traditionally, tumours from the same anatomical site are treated as one tumour entity. This concept has been challenged by recent breakthroughs in cancer genomics and translational research that have enabled molecular tumour profiling. The identification and validation of cancer drivers that are shared between different tumour types, spurred the new paradigm to target driver pathways across anatomical sites by off-label drug use, or within so-called basket or umbrella trials which are designed to test whether molecular alterations in one tumour entity can be extrapolated to all others. However, recent clinical and preclinical studies suggest that there are tissue- and cell type-specific differences in tumorigenesis and the organization of oncogenic signalling pathways. In this Opinion article, we focus on the molecular, cellular, systemic and environmental determinants of organ-specific tumorigenesis and the mechanisms of context-specific oncogenic signalling outputs. Investigation, recognition and in-depth biological understanding of these differences will be vital for the design of next-generation clinical trials and the implementation of molecularly guided cancer therapies in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–246 of 246
The regulatory roles of phosphatases in cancer
Stebbing, J., Lit, L. C., Zhang, H., Darrington, R. S., Melaiu, O., Rudraraju, B., & Giamas, G. (2013) · Oncogene · doi:10.1038/onc.2013.80 · Cited by 120
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells
Shojaee, S., Chan, L. N., Buchner, M., Cazzaniga, V., Cosgun, K. N., Geng, H., Qiu, Y. H., Minden, M. D.-V., Ernst, T., Hochhaus, A., et al. (2016) · Nature Medicine · doi:10.1038/nm.4062 · Cited by 118
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer
To, M. D., Wong, C. E., Karnezis, A. N., Rosario, R. D., Lauro, R. D., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117
Lichtenberger, B. M., Mastrogiannaki, M., & Watt, F. M. (2016) · Nature Communications · doi:10.1038/ncomms10537 · Cited by 117
Estrogen receptor α-mediated transcription induces cell cycle-dependent DNA double-strand breaks
Williamson, L. M., & Lees‐Miller, S. P. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq255 · Cited by 116
Zandstra, P. W., Lauffenburger, D. A., & Eaves, C. J. (2000) · Blood · doi:10.1182/blood.v96.4.1215 · Cited by 112
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 110
Haffner, M. C., Marzo, A. M. D., Meeker, A. K., Nelson, W. G., & Yegnasubramanian, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2044 · Cited by 108
Büchert, M., Athineos, D., Abud, H. E., Burke, Z. D., Faux, M. C., Samuel, M. S., Jarnicki, A., Winbanks, C. E., Newton, I. P., Méniel, V. S., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000816 · Cited by 106
Regulation of Cellular Identity in Cancer
Roy, N., & Hebrok, M. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.12.001 · Cited by 104
NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:
McNeil, C. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv193 · Cited by 103
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets
Eifert, C., & Powers, S. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3299 · Cited by 102
New cast for a new era: preclinical cancer drug development revisited
Herter-Sprie, G. S., Kung, A. L., & Wong, K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68340 · Cited by 102
Syndromic gastrointestinal stromal tumors
Ricci, R. (2016) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-016-0055-4 · Cited by 95
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 94
Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis
Young, N. P., Crowley, D. G., & Jacks, T. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4563 · Cited by 91
Life in the Fast Lane: Mammalian Disease Models in the Genomics Era
Dow, L. E., & Lowe, S. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.023 · Cited by 90
When Genome Maintenance Goes Badly Awry
Kass, E. M., Moynahan, M. E., & Jasin, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.021 · Cited by 87
Cancer lessons from mice to humans
Tuveson, D. A., & Hanahan, D. (2011) · Nature · doi:10.1038/471316a · Cited by 86
Guernet, A. A., Mungamuri, S. K., Cartier, D., Sachidanandam, R., Jayaprakash, A. D., Adriouch, S., Vézain, M., Charbonnier, F., Rohkin, G., Coutant, S., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.017 · Cited by 85
Cell of origin strongly influences genetic selection in a mouse model of T-ALL
Berquam‐Vrieze, K. E., Nannapaneni, K., Brett, B. T., Holmfeldt, L., Ma, J., Zagorodna, O., Jenkins, N. A., Copeland, N. G., Meyerholz, D. K., Knudson, C. M., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343947 · Cited by 84
Cell type-specific properties and environment shape tissue specificity of cancer genes
Schaefer, M. H., & Serrano, L. G. (2016) · Scientific Reports · doi:10.1038/srep20707 · Cited by 82
Tissue, cell and stage specificity of (epi)mutations in cancers
Sieber, O. M., Tomlinson, S. R., & Tomlinson, I. P. M. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1674 · Cited by 77
Fisher, R. A., Horswell, S. D., Rowan, A., Salm, M. P., de Bruin, E. C., Gulati, S., McGranahan, N., Stares, M., Gerlinger, M., Varela, I., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0433-z · Cited by 77
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
Wang, J., Khiabanian, H., Rossi, D., Fabbri, G., Gattei, V., Forconi, F., Laurenti, L., Marasca, R., Poeta, G. D., Foà, R., et al. (2014) · eLife · doi:10.7554/elife.02869 · Cited by 73
Fine-tuning T cell receptor signaling to control T cell development
Fu, G., Rybakin, V., Brzostek, J., Paster, W., Acuto, O., & Gascoigne, N. R. J. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.003 · Cited by 72
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
Muzumdar, M. D., Dorans, K. J., Chung, K. M., Robbins, R., Tammela, T., Gocheva, V., Li, C. M.-C., & Jacks, T. (2016) · Nature Communications · doi:10.1038/ncomms12685 · Cited by 72
Widespread genetic epistasis among cancer genes
Wang, X., Fu, A. Q., McNerney, M. E., & White, K. P. (2014) · Nature Communications · doi:10.1038/ncomms5828 · Cited by 68
BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia
Yaktapour, N., Meiß, F., Mastroianni, J., Zenz, T., Andrlová, H., Mathew, N. R., Claus, R., Hutter, B., Fröhling, S., Brors, B., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76539 · Cited by 67
Park, S., & Lehner, B. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156102 · Cited by 66
Tissue-specific p19 Arf regulation dictates the response to oncogenic K-ras
Young, N. P., & Jacks, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004796107 · Cited by 59
A porcine model of osteosarcoma
Saalfrank, A., Janssen, K., Ravon, M., Flisikowski, K., Eser, S., Steiger, K., Flisikowska, T., Müller-Fliedner, P., Schulze, É. A., Brönner, C., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.19 · Cited by 58
Self-citationPigs as models of human cancers
Flisikowska, T., Kind, A., & Schnieke, A. (2016) · Theriogenology · doi:10.1016/j.theriogenology.2016.04.058 · Cited by 57
BRAF: A Driver of the Serrated Pathway in Colon Cancer
Rustgi, A. K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.008 · Cited by 54
KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
Diersch, S., Wirth, M., Schneeweis, C., Jörs, S., Geisler, F., Siveke, J. T., Rad, R., Schmid, R. M., Saur, D., Rustgi, A. K., et al. (2015) · Oncogene · doi:10.1038/onc.2015.437 · Cited by 48
Self-citationZhu, C., Luong, R. H., Zhuo, M., Johnson, D. T., McKenney, J. K., Cunha, G. R., & Sun, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.269894 · Cited by 43
Wagner, E. F. (2016) · Nature · doi:10.1038/530042a · Cited by 37
From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue
Cohen, R. L., & Settleman, J. (2014) · Cell · doi:10.1016/j.cell.2014.05.027 · Cited by 29
Schaefer, M. H., Yang, J., Serrano, L. G., & Kiel, C. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003659 · Cited by 26
Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—A connection to licensing nodes
Schneeweis, C., Wirth, M., Saur, D., Reichert, M., & Schneider, G. (2016) · Small GTPases · doi:10.1080/21541248.2016.1262935 · Cited by 21
Self-citationLet's Not Put All Our Eggs in One Basket
Hunter, D. J., & D’Agostino, R. B. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1508144 · Cited by 17
Off-Label Use of Cancer Drugs: A Benchmark Is Established
Krzyzanowska, M. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9460 · Cited by 17
Basket Trials: Just the End of the First Quarter
Stenzinger, A., Weichert, W., Lennerz, J. K., & Klauschen, F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1516 · Cited by 13
Kras and Hras—what is the difference?
Berns, A. J. M. (2008) · Nature Genetics · doi:10.1038/ng1008-1149 · Cited by 12
Use of personalized cancer drugs runs ahead of the science
Mullard, A. (2015) · Nature · doi:10.1038/nature.2015.18389 · Cited by 7
Network evolution hinges on history
New, A. M., & Lehner, B. (2015) · Nature · doi:10.1038/nature14537 · Cited by 4
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597
Deep learning in cancer pathology: a new generation of clinical biomarkers
Echle, A., Rindtorff, N. T., Brinker, T. J., Luedde, T., Pearson, A. T., & Kather, J. N. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01122-x · Cited by 667
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
Rheinbay, E., Nielsen, M. M., Abascal, F., Wala, J. A., Shapira, O., Tiao, G., Hornshøj, H., Hess, J. M., Juul, R. I., Lin, Z., et al. (2020) · Nature · doi:10.1038/s41586-020-1965-x · Cited by 602
Molecular mechanisms linking exercise to cancer prevention and treatment
Hojman, P., Gehl, J., Christensen, J. F., & Pedersen, B. K. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.015 · Cited by 600
Metadata
- Authors
- Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D.
- Venue
- Nature Reviews Cancer
- Published
- 2017-03-03
- Volume
- 17
- Issue
- 4
- Pages
- 239-253
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2591757282
- Cited by
- 311
- References
- 246
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.